The Russian-made Sputnik V coronavirus vaccine has become an export hit. This opinion is expressed in the author’s article of the Swiss edition of the Neue Zurcher Zeitung, published on February 20.
The publication listed the advantages of the Russian drug over vaccines from Biontech / Pfizer and Moderna. Thus, the reliability of the RF vaccine is evidenced by the fact that it is based on the already studied adenoviral platform. In addition, the two doses of the vaccine use different carriers of the virus and are more effective than the structurally similar vaccine from AstraZeneca.
Also in favor of “Sputnik V” is its price, which is relatively low on the world market – $ 10 per dose. Finally, the vaccine can be stored at temperatures up to 8 degrees.
Commenting on the revealed advantages, the author of the publication concludes that the Russian vaccine has become an “export hit”.
Japanese analyst Kazuhiko Fuji also acknowledged the effectiveness of the Russian drug Sputnik V. after comparing different vaccines for coronavirus. The scientist recalled that the effectiveness of the Russian vaccine was confirmed at 92%.
On the eve of the Russian vaccine “Sputnik V” registered in Guyana. Ghana approved the drug on February 20.
In addition, the drug was approved in Belarus, Argentina, Bolivia, Algeria, Serbia, Paraguay, Palestine, Venezuela, United Arab Emirates, Turkmenistan, Hungary, Iran, Republic of Guinea, Tunisia, Armenia, Lebanon, Mexico, Nicaragua, Republika Srpska (subject of Bosnia and Herzegovina), Myanmar, Kazakhstan, Pakistan, Mongolia, Bahrain, Montenegro, Saint Vincent and the Grenadines, Uzbekistan and Gabon.
The world’s first COVID-19 vaccine Sputnik V was registered by the Russian Ministry of Health in August last year. It was developed by specialists from the Gamaleya Center on the basis of a studied and tested platform of human adenoviral vectors.
The final effectiveness of the drug was 91.4%, in relation to severe cases – 100%.